Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA Department of Neurology, Center for Human Experimental Therapeutics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA University of Rochester, Rochester, NY, USA Stanford University, Palo Alto, CA, USA Johns Hopkins University, Baltimore, MD, USA Oregon Health and Science University, Portland, OR, USA Northwestern University, Chicago, IL, USA University of Wisconsin, Madison, WI, USA University of Kiel, Kiel, Germany Schmerzfachpraxis, Krefeld, Germany University of Washington, Seattle, WA, USA Universität Heidelberg, Mannheim, Germany Pain Matters, Liverpool, UK.
Pain. 2013 Nov;154(11):2249-2261. doi: 10.1016/j.pain.2013.06.004. Epub 2013 Jun 6.
Neuropathic pain (NP) is often refractory to pharmacologic and noninterventional treatment. On behalf of the International Association for the Study of Pain Neuropathic Pain Special Interest Group, the authors evaluated systematic reviews, clinical trials, and existing guidelines for the interventional management of NP. Evidence is summarized and presented for neural blockade, spinal cord stimulation (SCS), intrathecal medication, and neurosurgical interventions in patients with the following peripheral and central NP conditions: herpes zoster and postherpetic neuralgia (PHN); painful diabetic and other peripheral neuropathies; spinal cord injury NP; central poststroke pain; radiculopathy and failed back surgery syndrome (FBSS); complex regional pain syndrome (CRPS); and trigeminal neuralgia and neuropathy. Due to the paucity of high-quality clinical trials, no strong recommendations can be made. Four weak recommendations based on the amount and consistency of evidence, including degree of efficacy and safety, are: 1) epidural injections for herpes zoster; 2) steroid injections for radiculopathy; 3) SCS for FBSS; and 4) SCS for CRPS type 1. Based on the available data, we recommend not to use sympathetic blocks for PHN nor radiofrequency lesions for radiculopathy. No other conclusive recommendations can be made due to the poor quality of available data. Whenever possible, these interventions should either be part of randomized clinical trials or documented in pain registries. Priorities for future research include randomized clinical trials, long-term studies, and head-to-head comparisons among different interventional and noninterventional treatments.
神经病理性疼痛(NP)通常对药物和非介入治疗有抗性。代表国际疼痛研究协会的神经病理性疼痛特别兴趣小组,作者评估了神经阻滞、脊髓刺激(SCS)、鞘内药物和神经外科干预的介入管理的系统评价、临床试验和现有指南。证据在以下周围和中枢 NP 疾病的患者中进行了总结和呈现:带状疱疹和带状疱疹后神经痛(PHN);痛性糖尿病和其他周围神经病变;脊髓损伤 NP;中风后中枢性疼痛;神经根病和后路手术失败综合征(FBSS);复杂性区域疼痛综合征(CRPS);以及三叉神经痛和神经病变。由于高质量临床试验的缺乏,无法做出强烈建议。基于证据的数量和一致性,包括疗效和安全性程度,提出了四项弱建议:1)带状疱疹的硬膜外注射;2)神经根病的类固醇注射;3)FBSS 的 SCS;4)CRPS 1 型的 SCS。基于现有数据,我们建议不要将交感神经阻滞用于 PHN,也不要将射频损伤用于神经根病。由于现有数据质量较差,无法做出其他明确建议。只要有可能,这些干预措施应作为随机临床试验的一部分,或记录在疼痛登记处。未来研究的重点包括随机临床试验、长期研究以及不同介入和非介入治疗之间的头对头比较。